Canaccord Genuity Analysts Begin Coverage on Newlink Genetics Cor (NLNK)

By admin | 6 years ago

Equities researchers at Canaccord Genuity began coverage on shares of Newlink Genetics Cor (NASDAQ: NLNK) in a report issued on Friday. The firm set a “buy” rating on the stock.

Shares of Newlink Genetics Cor traded down 5.35% during mid-day trading on Friday, hitting $11.86. Newlink Genetics Cor has a one year low of $6.25 and a one year high of $13.67. The company’s market cap is $245.2 million.

NLNK has been the subject of a number of other recent research reports. Analysts at Stifel Nicolaus raised their price target on shares of Newlink Genetics Cor from $16.00 to $19.00 in a research note to investors on Friday, May 25th. They now have a “buy” rating on the stock. Analysts at Robert W. Baird reiterated an “outperform” rating on shares of Newlink Genetics Cor in a research note to investors on Friday, March 30th.

NewLink Genetics Corporation (NewLink) is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment.

About the author